^aIQVIA SMART Portal Patient Insights as of June 2026.

^bThis worldwide number is largely comprised from 11 countries (Brazil, Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, the UK, and the US), with the rest of the world comprising ≈12% of this number. This number is comprised of the following US approved indications: AD, asthma, BP, COPD, CRSwNP, CSU, PN, and EoE. Data through March 2026.